Skip to content

iDose® TR Patient Savings Program Terms & Conditions

The iDose TR Patient Savings Program (“Program”) is valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication for iDose TR. Patients using Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD), TRICARE or any other federal or state government program (collectively, “Government Programs”) to pay for iDose TR and/or administration services are not eligible. The Program is not valid if the costs are eligible to be reimbursed in their entirety by commercial insurance plans or other programs.

Under the Program, the patient may be required to pay a co-pay. The final amount owed by a patient may be as little as $0 for iDose TR, one implant per eye. The total patient out-of-pocket cost is dependent on the patient’s health insurance plan. The Program assists with the cost of iDose TR. It does not assist with the cost of other administrations, medicines, procedures, or office visit fees. The Program benefit amounts cannot exceed the patient’s out-of-pocket expenses for iDose TR. The Program is not health insurance or a benefit plan. The patient’s non-governmental insurance is the primary payer. 

Once a patient is enrolled, the Program will honor claims with a date of service that precedes Program enrollment by 180 days. Claims must be submitted within 180 days from the date of service unless otherwise indicated. Use of this Program must be consistent with all relevant health insurance requirements. Participating patients, pharmacies, physicians’ offices and hospitals are responsible for reporting the receipt of all the Programs’ benefits as required by any insurer or by law. Program benefits may not be sold, purchased, traded or offered for sale.

The patient or their guardian must be 18 years of age or older to receive assistance from the Program. The Program is only valid in the United States and U.S. Territories and are void where prohibited by law.

The value of the Program is intended exclusively for the benefit of the patient. The funds made available through the Program may only be used to reduce the out-of-pocket costs for the patient enrolled in the Program.

Glaukos reserves the right at any time to delete, modify, or change the terms and conditions without notice.

Important Safety Information

iDose TR is gently placed directly inside your eye by your eye doctor.

You should not have iDose TR if you have an infection or suspected infection in your eye or the area surrounding your eye, have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally as this can cause vision problems, have had a corneal transplant or cells transplanted to the inner layer of the cornea (endothelial cell transplant), are allergic to any of its ingredients, and/or have narrow angles (the iris and the cornea are too close together).

The most common side effect of iDose TR was increased eye pressure. Other common side effects were inflammation of the iris, dry eye, a loss of part of the usual field of vision, eye pain, eye redness and reduced clearness of vision.

If you have additional questions, please contact your doctor. For full Prescribing Information click here.

Approved Uses

iDose TR (travoprost intracameral implant) is a prescription medicine and drug delivery system for the eye approved to lower eye pressure in patients with open-angle glaucoma or high eye pressure (ocular hypertension).

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.